[Peripheral anticholinergic syndrome].
This is a case report of a woman of 38 years old, studied and analyzed at the service of allergy and immunology with clinical manifestations of allergic rhinitis; studies of laboratory, cabinet and intradermal test were made to corroborate this diagnosis and the treatment with specific hyposensitization, oral antihistaminines and inhaled steroids was started. Two years later the patient referred urinary retention without important antecedents, so, a peripheral anticholinergic syndrome (PAS) was suspected, a urodynamic test study was carried out consisting in a uroflujometry, static and dynamic urethral profile, cystometry, flow pressure study and electromyography, which diagnosed low urinary obstruction (functional) and vesical sphincter pseudodysfunction, demonstrating the PAS associated with oral antihistamines.
Valencia Zavala
Martha Patricia
MP
Médica adscrita al servicio de alergia e inmunología clínica, Hospital General de México. mipsins@hotmail.com
Vega Robledo
Gloria Bertha
GB
Sánchez Olivas
Jesús Alberto
JA
Sánchez Olivas
Manuel A
MA
Montes Montes
José
J
Duarte Díaz
Rosa Janet
RJ
León Oviedo
Cristóbal
C
D000328:Adult; D000342:Affective Symptoms / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002090:Butyrophenones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002100:Cachexia / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003951:Diagnostic Errors; D004359:Drug Therapy, Combination; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007665:Ketotifen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017336:Loratadine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068656:Mometasone Furoate; D019964:Mood Disorders / Q000175:diagnosis; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D016055:Urinary Retention / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology
D018926:Anti-Allergic Agents; D002090:Butyrophenones; D018680:Cholinergic Antagonists; D006634:Histamine H1 Antagonists; D039563:Histamine H1 Antagonists, Non-Sedating; D010880:Piperidines; D011244:Pregnadienediols; D011976:Receptors, Muscarinic; D000068656:Mometasone Furoate; D017336:Loratadine; C058249:ebastine; D007665:Ketotifen